Cargando…
Assessment of early response biomarkers in relation to long‐term survival in patients with HER2‐negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial
Pathologic complete response (pCR) is a predictor for favorable outcome after neoadjuvant treatment in early breast cancer. Modulation of gene expression may also provide early readouts of biological activity and prognosis, offering the possibility for timely response‐guided treatment adjustment. Th...
Autores principales: | Kimbung, Siker, Markholm, Ida, Bjöhle, Judith, Lekberg, Tobias, von Wachenfeldt, Anna, Azavedo, Edward, Saracco, Ariel, Hellström, Mats, Veerla, Srinivas, Paquet, Eric, Bendahl, Pär‐Ola, Fernö, Mårten, Bergh, Jonas, Loman, Niklas, Hatschek, Thomas, Hedenfalk, Ingrid |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765477/ https://www.ncbi.nlm.nih.gov/pubmed/28940389 http://dx.doi.org/10.1002/ijc.31070 |
Ejemplares similares
-
Cancer‐associated fecal microbial markers in colorectal cancer detection
por: Eklöf, Vincy, et al.
Publicado: (2017) -
Predictive value of chromosome 18q11.2‐q12.1 loss for benefit from bevacizumab in metastatic colorectal cancer: A post hoc analysis of the randomized phase III‐trial AGITG‐MAX
por: van Dijk, Erik, et al.
Publicado: (2022) -
High hemoglobin A1c levels within the non‐diabetic range are associated with the risk of all cancers
por: Goto, Atsushi, et al.
Publicado: (2015) -
High‐resolution imaging for the detection and characterisation of circulating tumour cells from patients with oesophageal, hepatocellular, thyroid and ovarian cancers
por: Dent, Barry M., et al.
Publicado: (2015) -
Protein Z: A putative novel biomarker for early detection of ovarian cancer
por: Russell, Matthew R., et al.
Publicado: (2016)